|
業務類別
|
Biotechnology |
|
業務概覽
|
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets. |
| 公司地址
| 42 Hayarkon Street, Yavne, ISR, 8122745 |
| 電話號碼
| +972 779714100 |
| 傳真號碼
| +972 779714111 |
| 公司網頁
| https://www.mediwound.com |
| 員工數量
| 111 |
| Mr. Shmulik Hess |
Chief Operating Officer and Chief Commercial Officer |
美元 340.00K |
05/03/2026 |
| Mr. Yaron Meyer |
Executive Vice President, General Counsel and Corporate Secretary |
美元 272.00K |
05/03/2026 |
| Mr. Ofer Gonen |
Chief Executive Officer |
美元 634.00K |
05/03/2026 |
| Dr. Ety Klinger, M.S.,PhD |
Chief Medical Officer |
美元 320.00K |
05/03/2026 |
| Ms. Hani Luxenburg |
Chief Financial Officer |
美元 314.00K |
05/03/2026 |
|
|
| Mr. Nachum Shamir |
Chairman of the Board |
05/03/2026 |
| Mr. Stephen T. Wills |
Independent Director |
05/03/2026 |
| Dr. Vickie R. Driver |
Independent Director |
05/03/2026 |
| Mr. David Fox |
Independent Director |
05/03/2026 |
| Mr. Shmuel Rubinstein |
Independent Director |
05/03/2026 |
|
|
|
|
